Quantbot Technologies’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-5,300
Closed -$4.55K – 2064
2023
Q4
$4.55K Hold
5,300
– – ﹤0.01% 1495
2023
Q3
$5.67K Sell
5,300
-200
-4% -$414 ﹤0.01% 1446
2023
Q2
$14.2K Buy
5,500
+1,524
+38% +$5.44K ﹤0.01% 1440
2023
Q1
$16.2K Sell
3,976
-5,342
-57% -$24.7K ﹤0.01% 1372
2022
Q4
$46.8K Buy
9,318
+8,790
+1,665% +$55.1K ﹤0.01% 1318
2022
Q3
$6K Sell
528
-5,404
-91% -$81.8K ﹤0.01% 1470
2022
Q2
$76K Buy
5,932
+4,505
+316% +$62.4K 0.01% 1216
2022
Q1
$21K Sell
1,427
-3,773
-73% -$58.8K ﹤0.01% 1355
2021
Q4
$92K Buy
5,200
+3,800
+271% +$72.9K 0.01% 895
2021
Q3
$29K Buy
+1,400
New +$30.8K ﹤0.01% 1208
2021
Q1
– Sell
-200
Closed -$6K – 1844
2020
Q4
$6K Buy
+200
New +$4.38K ﹤0.01% 1153
2020
Q3
– Sell
-82
Closed -$1K – 1720
2020
Q2
$1K Buy
+82
New +$1.57K ﹤0.01% 1076

Other funds holding NGM

Quantbot Technologies's NGM Position: Q1 2024 in Review

Quantbot Technologies sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 5,300 shares — an estimated $4.55K sold.

Quantbot Technologies first reported a position in NGM in Q2 2020 and held it in 12 quarters. The position peaked at $92K in Q4 2021. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Quantbot Technologies reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Quantbot Technologies sold 5,300 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $4.55K.
  • Quantbot Technologies first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Quantbot Technologies's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $92K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Quantbot Technologies's 13F filing for Q1 2024, filed 6 May 2024.